Common Acute Lymphoblastic Leukemia: Disease Bioinformatics
Childhood Acute Lymphoblastic Leukemia is a fast growing type of blood cancer. The cancer is characterized by the high levels of lymphoblasts in both the blood and bone marrow. The cancer can then spread to other organs in the body and without treatment Childhood Acute Lymphoblastic Leukemia will progress very quickly. Childhood Acute Lymphoblastic Leukemia may arise from transformation of B or T cell progenitor cells. Once there are no traces of leukemia in the body through a series of tests the patient is considered to be in remissiom. Although it is not garunteed that the leukemia witll continue to be in remission, often a petient will go through a relapse where the cancer returns.
Common Acute Lymphoblastic Leukemia Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Common Acute Lymphoblastic Leukemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 2007 products for the study of Common Acute Lymphoblastic Leukemia that can be applied to Western Blot, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Common Acute Lymphoblastic Leukemia is also known as Common Acute Lymphoblastic Leukaemia.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.